Barrett's adenocarcinoma of the esophagus - Better outcomes through new methods of diagnosis and treatment;Barrett-karzinom der speiseröhre - Prognoseverbesserung durch innovationen in diagnostik und therapie

Deutsches Arzteblatt

Volumn 108, Issue 18, 2011, Pages 313-319

  Behrens, Angelika ^a   Pech, Oliver ^a   Graupe, Florian ^a   May, Andrea ^a   Lorenz, Dietmar ^a   Ell, Christian ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ARTICLE; BARRETT ESOPHAGUS; CANCER ADJUVANT THERAPY; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; HUMAN; MOLECULAR THERAPY; MORBIDITY; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HUMANS;

EID: 79959471410     PISSN: 00121207     EISSN: 01722107     Source Type: Journal    
DOI: 10.3238/arztebl.2011.0313     Document Type: Article

References (25)

1. Koop H, Schepp W, Müller-Lissner S, et al.: Gastrosophageale Refluxkrankheit - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Z Gastroenterol 2005; 43: 163-4. (Pubitemid 40332908)
2. Cunningham D, Allum WH, Stenning S, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. NEJM 2006; 355: 11-20.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010; 376: 687-97.
4. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-6. (Pubitemid 40277094)
5. Brown LM, Devesa SS, Chow WH: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100: 1184-7.
6. Lagergren J, Bergström R, Lindgren A, Nyrén O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31. (Pubitemid 29142625)
7. Spechler SJ: Barrett's esophagus. NEJM 2002; 346: 836-42.
8. Sharma P, Falk GW, Sampliner R, Spechler SJ, Wang K: Management of nondysplastic Barrett's esophagus: Where are we now? Am J Gastroenterol 2009; 104: 805-8.
9. Chak A, Falk G, Grady WM, et al.: Assessment of familiality, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction. Am J Gastroenterol 2009; 104: 1913-21.
10. Hampel H, Abraham NS, El-Serag HB: Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Int Med 2005; 143: 199-211. (Pubitemid 41076753)
11. Wu A, Wan P, Bernstein L: A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 2001; 12: 721-32. (Pubitemid 32807718)
12. Pech O, May A, Günter E, et al.: The impact of endoscopic ultrasound and computed tomography on the TNM staging of early cancer in Barrett's esophagus. Am J Gastroenterology 2006; 101: 2223-9. (Pubitemid 44477547)
13. Oka S, Tanaka S, Kaneko I, et al.: Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc 2006; 64: 877-83. (Pubitemid 44829827)
14. Imagawa A, Okada H, Kawahara Y, et al.: Endoscopic submucosal dissection for early gastric cancer: results and degrees of technical difficulty as well as success. Endoscopy 2006; 38: 987-90. (Pubitemid 44615233)
15. Ell C, May A, Gossner L, Pech O, et al.: Kurative endoskopische Therapie früher Adenokarzinome der Speiseröhre. Dtsch Arztebl 2003; 100(21): A 1438.
16. Pech O, Behrens A, May A, et al.: Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57: 1200-6.
17. Pech O, Manner H, May A, et al.: Endoscopic therapy in 1059 patients with high grade dysplasia and early adenocarcinoma in Barrett's esophagus - Lessons we have learned. Gastrointestinal Endoscopy 2009; 69: AB114-5.
18. Pacifico RJ, Wang KK, Wongkeesong LM, et al.: Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastro Hepatol 2003; 1: 252-7. (Pubitemid 37254451)
19. Buttar NS, Wang KK, Lutzke LS, et al.: Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointestinal Endoscopy 2001; 54: 682-8. (Pubitemid 33668674)
20. Peters FP, Kara MA, Rosmolen WD, et al.: Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. Gastrointest Endosc 2005; 61: 506-14. (Pubitemid 40462188)
21. Birkmeyer JD, Siewers EA, Finlayson EVA, et al.: Hospital volumen und surgical lethality in the United States. N Engl J Med 2002; 15: 1128-37. (Pubitemid 34984604)
22. Skipworth RJ, Parks RW, Stephens NA, et al.: The relationship between hospital volume and post-operative mortality rates for upper gastrointestinal cancer resections: Scotland 1982-2003. Eur J Surg Oncol 2010; 36: 141-7.
23. Omloo JM, Law SY, Launois B, et al.: Short and long-term advantages of transhiatal and transthoracic oesophageal cancer resection. Eur J Surg Oncol 2009; 35: 793-7.
24. Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al.: Minimally invasive esophagectomy. Outcomes in 222 patients. Annals Surg 2003; 238: 486-95.
25. Stein HJ, Feith M, Mueller J, et al.: Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg 2000; 232: 733-42.